CABA: Cabaletta Bio Inc. Price to Sales
Cabaletta Bio, Inc. (CABA) develops innovative medicines for autoimmune pathologies, leveraging a scientific alliance with the University of Pennsylvania. The price-to-sales ratio reflects the issuer's valuation dynamics, with the current mark standing at . AI systems and robotic bioscreening are accelerating business growth, while the high cost of clinical validation combined with CAR-T patents create a robust defensive barrier.
Analytical breakdowns for Cabaletta Bio, Inc (CABA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- business earnings and investment ratios data:
CABA - Net Income|Future Net Profit Cabaletta Bio, Inc.|CABA - P/E Multiple|Forward P/E Multiple Cabaletta Bio Inc.|CABA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Cabaletta Bio, Inc|CABA - Operating profit EBITDA|Earnings per share for the last twelve months Cabaletta Bio, Inc.|CABA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months cabalettabio.com|CABA - Earnings per share growth in current year|Expected net earnings per share growth next year Cabaletta Bio, Inc.
- issuer revenue and sales details:
Fundamental company analysis:cabalettabio.com CABA
For Cabaletta Bio, Inc. (CABA), whose valuation is based on CAR-T therapy patents and stringent FDA barriers, the P/S ratio reflects the market value of every dollar of revenue. This chart is calculated as the ratio of market capitalization to annual turnover, allowing the investor to assess the degree of overpayment for the asset and determine the current phase of the biotechnology business capitalization cycle.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|Protagonist Corp (PTGX) - Market Cap to Revenue|IMVT: P/S Multiple|kiniksa.com (KNSA) - P/S Multiple|GRFS (Grifols) - P/S Multiple|Price-to-Revenue Ratio ADPT|P/S Multiple CLDX|P/S Multiple Aurinia Corp (AUPH)|Price-to-Revenue Ratio BioCryst BCRX|veratx.com - Price-to-Revenue Ratio|Dianthus Therapeutics, Inc. - P/S Multiple|Price to Sales Pharvaris NV|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|TRML: Market Cap to Sales Volume|Market Cap to Revenue PGEN|PHAR (pharming.com) - Market Cap to Sales Volume|P/S Multiple NKTR|P/S Multiple Upstream Bio, Inc. (UPB)|Zenas Biopharma, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMNM|Gossamer Bio, Inc. - P/S Multiple|KALV: Price-to-Revenue Ratio|SEPN: P/S Multiple|PVLA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Savara Corp|Price to Sales Rigel Corp RIGL|Market Cap to Revenue ANAB (AnaptysBio, Inc.)|ATXS (astriatx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENGN (enGene)|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|JBIO - Price-to-Revenue Ratio|ACRS (Aclaris Therapeutics, Inc) - Market Cap to Revenue Ratio|KYTX: P/S Multiple|Market Cap to Revenue tizianalifesciences.com|Market Cap to Revenue VTYX|Theratechnologies, Inc. (THTX) - Price-to-Revenue Coefficient|P/S Multiple AVTX|Market Cap to Revenue Eledon Pharmaceuticals, Inc ELDN|P/S Multiple AGEN (Agenus)|P/S Multiple climbbio.com CLYM|Zura Bio - P/S Multiple|ATYR: Price-to-Revenue Ratio|ADAG: P/S Multiple|Ikena Oncology (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Labs Inc|Equillium Bio - Price-to-Sales Ratio|P/S Multiple CNTB|IMUX (immunic-therapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ATRA (Atara Bio)|P/S Multiple InflaRx NV IFRX|XFOR - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ACET (Adicet Bio)|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|Market Cap to Revenue SABS (SAB Biotherapeutics)|AKTX (akaritx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Price-to-Revenue Coefficient Q32 Bio Inc (QTTB)|GOVX - Price-to-Revenue Ratio|Edesa Biotech Corp (EDSA) - Market Cap to Revenue|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Market Cap to Revenue Carisma Therapeutics Inc.|Market Cap to Revenue XTLB|P/S Multiple Bolt Bio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple AIM (AIM ImmunoTech Inc.)|Aditxt Inc. (ADTX) - Price to Sales|GRI Bio - P/S Multiple|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND: P/S Multiple|Revelation Biosciences Corp (REVB) - P/S Multiple|INDP (Indaptus Therapeutics) - P/S Multiple|Price-to-Revenue Ratio SCNI|P/S Multiple CALI|P/S Multiple affimed.com (AFMD)|Price-to-Revenue Ratio Allakos ALLK|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGM Bio - P/S Multiple|Price to Sales iteostherapeutics.com|OCEA (Ocean Biomedical) - Market Cap to Revenue|TCBP: Market Cap to Sales Volume|Market Cap to Revenue THRD
